Immunocore Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$IMCR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 27, 2026
(Exact name of registrant as specified in its Charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
+44 1235 438600
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
* Not for trading, but only in connection with the listing of the
American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
On May 27, 2026, Immunocore Holdings plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The
shareholders considered the ten resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company’s definitive proxy statement filed with the Securities and
Exchange Commission on April 16, 2026 (the “Proxy Statement”). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the
AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution.
Ordinary Resolutions
Resolution 1: To re-appoint as a director of
the Company Siddharth Kaul. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,033,664
|
261,819
|
8,357
|
Resolution 2: To re-appoint as a director of
the Company William Pao, M.D., Ph.D. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,040,755
|
254,852
|
8,233
|
Resolution 3: To re-appoint as a director of
the Company Kristine Peterson. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
29,537,800
|
8,744,383
|
21,657
|
Resolution 4: To approve, on an advisory
basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
29,682,169
|
8,600,029
|
21,642
|
Resolution 5: To ratify the appointment of
Deloitte LLP, a limited liability partnership organized under the laws of England, as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,294,666
|
984
|
8,190
|
Resolution 6: To re-appoint Deloitte LLP, a
limited liability partnership organized under the laws of England, as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,294,523
|
966
|
8,351
|
Resolution 7: To authorize the audit committee
to determine the U.K. statutory auditors’ remuneration for the year ending December 31, 2026. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,293,269
|
2,481
|
8,090
|
Resolution 8: To receive and adopt the U.K.
statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,287,987
|
944
|
14,909
|
Resolution 9: To approve the directors’
remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 26 to 56 of the 2025 U.K. Annual Report (excluding the directors’ remuneration policy set out on pages A-5 to A-15 of Annex
A to the Proxy Statement). The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
29,504,692
|
8,713,573
|
85,575
|
Resolution 10: To authorize the Company to
make political donations/incur political expenditure. The votes were cast as follows:
|
For
|
Against
|
Abstain
|
|
38,213,340
|
82,113
|
8,387
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IMMUNOCORE HOLDINGS PLC
|
|||
|
Dated: May 27, 2026
|
By:
|
/s/ Bahija Jallal, Ph.D.
|
|
|
Name:
|
Bahija Jallal, Ph.D.
|
||
|
Title:
|
Chief Executive Officer
|
||